Active Watch List: Acorda Therapeutics (NASDAQ:ACOR), American Airlines Group Inc. (NASDAQ:AAL), Aehr Test Systems (NASDAQ:AEHR), Merck (NYSE:MRK), NewStar Financial (NASDAQ:NEWS)

On Thursday shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) closed at $33.51. Company’s sales growth for last 5 years was 49.00% and EPS growth for next 5 years is recorded as 32.00%. Zacks reissued their strong-buy rating on shares of Acorda Therapeutics, Inc. (NASDAQ:ACOR) in a research note released on Monday morning. They currently have a $39.00 target price on the stock.

American Airlines Group Inc. (NASDAQ:AAL) in last trading activity decreased -2.51% to close at $49.17. Company weekly performance is -4.09% while its quarterly performance stands at -8.12%. American Airlines Group Inc. (NASDAQ:AAL) is -12.33% away from its 52 week high. On 31 March, American Airlines Group Inc. (NASDAQ:AAL) said that, it resumed nonstop services to a handful of locations and added a new daily service from the Philadelphia International Airport.

On Thursday shares of Aehr Test Systems (NASDAQ:AEHR) closed at $2.06. Company’s sales growth for last 5 years was -1.60% and EPS growth for next 5 years is recorded as 20.00%. On 26 March, Aehr Test Systems (NASDAQ:AEHR) announced financial results for its third quarter of fiscal 2015 ended February 28, 2015. Net sales in the third quarter of fiscal 2015 were $2.0 million, compared to $2.6 million in the second quarter of fiscal 2015. Aehr Test reported a non-GAAP net loss of $1.5 million, or $0.12 per diluted share, and a GAAP net loss of $1.7 million, or $0.14 per diluted share, in the third quarter of fiscal 2015.

Merck & Co. Inc. (NYSE:MRK) in last trading activity advanced 0.42% to close at $57.10. Company weekly performance is -0.87% while its quarterly performance stands at 1.37%. Merck & Co. Inc. (NYSE:MRK) is -9.52% away from its 52 week high. On 1 April, Merck & Co. Inc. (NYSE:MRK) said that, it has reached an agreement to test Keytruda (pembrolizumab)alongside Syndax’s histone deacetylase (HDAC) inhibitor entinostat in phase Ib/II trials in melanoma and non-small cell lung cancer (NSCLC), with a view to progressing quickly to full-blown phase III studies.

On last trading day NewStar Financial, Inc. (NASDAQ:NEWS) fell -1.92% to close at $11.76. Its volatility for the week is 7.10% while volatility for the month is 5.54%. NEWS’s sales growth for past 5 years was 0.70% and its EPS growth for past 5 years was 17.40%. NewStar Financial, Inc. (NASDAQ:NEWS) monthly performance is 21.11%. NewStar Financial, Inc. (NASDAQ:NEWS) announced that it has hired veteran banker Paul Horton as a Managing Director in its Leveraged Finance group with responsibility for generating new financing opportunities with mid-sized companies, private equity firms and other investors in the middle market.

Leave a Reply

Your email address will not be published. Required fields are marked *

*